Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Klaus Flechsenhar"'
Autor:
Jeffrey B. Driban, Lori Lyn Price, Bing Lu, Klaus Flechsenhar, Grace H. Lo, Timothy E. McAlindon
Publikováno v:
Seminars in Arthritis and Rheumatism. 58:152148
We aimed to describe the natural history leading to end-stage knee osteoarthritis (esKOA), focusing on knee symptoms, radiographic severity, and the presence of limited mobility or instability.We performed knee-based analyses of Osteoarthritis Initia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56d386a7939dfa2fbca013c88629c8cf
https://doi.org/10.1016/j.semarthrit.2022.152148
https://doi.org/10.1016/j.semarthrit.2022.152148
Publikováno v:
Seminars in Arthritis and Rheumatism. 49:3-8
Objective We previously published data representing calculations for sample sizes assuming that the reduction of the incidence of knee joint replacement (KJR) would be an endpoint to prove efficacy of a disease-modifying drug in osteoarthritis (DMOAD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b129f17e5235302de72cb0f2b4badf
https://doi.org/10.1016/j.semarthrit.2018.12.002
https://doi.org/10.1016/j.semarthrit.2018.12.002
Autor:
Paul J. Bryce, Danping Ding-Pfennigdorff, Matthias Herrmann, Klaus Flechsenhar, Frank O. Nestle, Peter Florian, Eckart Bartnik
Publikováno v:
Experimental Dermatology. 29:4-14
Due to the clinical development of drugs such as secukinumab, ustekinumab and dupilumab, major changes have been achieved in the treatment of patients diagnosed with psoriasis and atopic dermatitis. In academia and the pharmaceutical industry, resear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf98dacd784da77d4ec6f678bb7110cf
https://doi.org/10.1111/exd.13942
https://doi.org/10.1111/exd.13942
Autor:
Daniel Crowther, Axel Dietrich, Janina S. Ried, Klaus Flechsenhar, Felix Eckstein, Eckart Bartnik
Publikováno v:
Arthritis & Rheumatology. 67:3174-3183
Objective To evaluate the extent to which the current designs of clinical trials in knee osteoarthritis (OA) permit detection of a therapeutic effect of disease-modifying OA drugs (DMOADs) on the incidence of knee replacement, and to provide estimate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e491b48aeb1b87da27b3246d7069323
https://doi.org/10.1002/art.39334
https://doi.org/10.1002/art.39334
Publikováno v:
Journal of Arthritis. 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::debcb10ebb900aa1a0972d01c1bfe989
https://doi.org/10.4172/2167-7921.1000219
https://doi.org/10.4172/2167-7921.1000219
Autor:
David Burstein, John L. Griffith, Lori L. Price, M. Nuite, Klaus Flechsenhar, Nitya Krishnan, Timothy E. McAlindon, Robin Ruthazer
Publikováno v:
Osteoarthritis and Cartilage. 19(4):399-405
summary Objective: To determine whether either of two magnetic resonance imaging approaches e delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC), or T2 mapping e can detect short-term changes in knee hyaline cartilage among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c34a1047fec77828be54b682add6fe35
Autor:
Steffen Dr. Oesser, Klaus Flechsenhar, Burkhard Schlosshauer, M. Suckfuell, Michael Ahlers, Reiner Hajosch
Publikováno v:
Journal of Biomedical Materials Research Part B: Applied Biomaterials. :372-379
To more effectively manage the substantial bleeding encountered during surgical procedures in oto-rhino-laryngology, we developed a novel hemostatic sponge made of pharmaceutical grade, chemically cross-linked gelatin. The sponge is characterized by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abf8cc9a31faa0b46d287b3c6ac126c
https://doi.org/10.1002/jbm.b.31663
https://doi.org/10.1002/jbm.b.31663
Autor:
Janina S, Ried, Klaus, Flechsenhar, Eckart, Bartnik, Daniel, Crowther, Axel, Dietrich, Felix, Eckstein
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.). 67(12)
To evaluate the extent to which the current designs of clinical trials in knee osteoarthritis (OA) permit detection of a therapeutic effect of disease-modifying OA drugs (DMOADs) on the incidence of knee replacement, and to provide estimates of the r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8274f1ca1aa2cb28930edcfa74f782e7
https://pubmed.ncbi.nlm.nih.gov/26314914
https://pubmed.ncbi.nlm.nih.gov/26314914
Autor:
Eckart Bartnik, Lenore Teichert, Janina S. Ried, Timothy E. McAlindon, Matthias Herrmann, Klaus Flechsenhar
Publikováno v:
Journal of Biomedical Research
To evaluate in an interventional trial on knee osteoarthritis (OA) the level and change of two serum biomarkers and their correlation with imaging parameters. The previously reported interventional OA study (ClinicalTrials.gov: NCT00536302) identifie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7720582aea1dd577849a24af0a2c5d16
https://doi.org/10.7555/jbr.31.20150167
https://doi.org/10.7555/jbr.31.20150167
Publikováno v:
World Journal of Surgery. 25:1367-1372
The primitive neuroectodermal tumor (PNET) is an extremely aggressive soft tissue neoplasm that occurs in children and adolescents. We retrospectively reviewed our therapeutic experience with a multidisciplinary approach, combining surgery, chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8006ac0227dbfd3fa8117e7706c03a70
https://doi.org/10.1007/s00268-001-0142-0
https://doi.org/10.1007/s00268-001-0142-0